Don't Rush to Prescribe Olumiant or Xeljanz XR for Rheumatoid Arthritis

December 2018

Olumiant (baricitinib) and Xeljanz XR (tofacitinib) will be new once-daily oral meds for rheumatoid arthritis (RA).

Olumiant (oh-LOO-mee-ant) is the second Janus kinase (JAK) inhibitor for RA on the market after Xeljanz.

And now once-daily Xeljanz XR may simplify dosing over Xeljanz BID.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote